Mercy Hospital & Health Services Contact Us
MyChart
About Mercy
Join Our Team
set font size large set font size medium set font size small
email this page print this page
BIPI 1237 Banner

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Sponsored by Boehringer Ingelheim Pharmaceuticals


Purpose


The primary objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components ( tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD).

 
ConditionInterventionPhase
Pulmonary Disease, Chronic
Obstructive
Drug: tiotropium+olodaterol
FDC
Drug: olodaterol
Drug: tiotropium
Phase III

ArmsAssigned Interventions
tiotropium+olodaterol low dose FDC:
Experimental
Once daily 2 puffs solution for inhalation
Respimat
Intervention: Drug: tiotropium+olodaterol
FDC
Drug: tiotropium+olodaterol FDC
low dose or high dose
tiotropium+olodaterol high dose FDC:
Experimental
Once daily 2 puffs solution for inhalation
Respimat
Intervention: Drug: tiotropium+olodaterol
FDC
Drug: tiotropium+olodaterol
FDC
low dose or high dose
olodaterol: Active Comparator
Once daily 2 puffs solution for inhalation
Respimat
Intervention: Drug: olodaterol
Drug: olodaterol
one dose only
tiotropium low dose: Active Comparator
Once daily 2 puffs solution for inhalation
Respimat
Drug: tiotropium
low dose or high dose
Intervention: Drug: tiotropium 
tiotropium high dose: Active Comparator
Once daily 2 puffs solution for inhalation
Respimat
Intervention: Drug: tiotropium
Drug: tiotropium
low dose or high dose

separator

Eligibility


Ages Eligible for Study:40 Years and older
Genders Eligible for Study:Both
Accepts Health VolunteersNo

Criteria

Inclusion criteria:
  1. Diagnosis of chronic obstructive pulmonary disease.
  2. Relatively stable airway obstruction with post FEV1< 80% predicted normal and post FEV1/FVC <70%.
  3. Male or female patients, 40 years of age or older.
  4. Smoking history of more than 10 pack years.
Exclusion criteria:
  1. Significant disease other than COPD
  2. Clinically relevant abnormal lab values.
  3. History of asthma.
  4. Diagnosis of thyrotoxicosis
  5. Diagnosis of paroxysmal tachycardia
  6. History of myocardial infarction within 1 year of screening visit
  7. Unstable or life-threatening cardiac arrhythmia.
  8. Hospitalization for heart failure within the past year.
  9. Known active tuberculosis.
  10. Malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years
  11. History of life-threatening pulmonary obstruction.
  12. History of cystic fibrosis.
  13. Clinically evident bronchiectasis.
  14. History of significant alcohol or drug abuse.
  15. Thoracotomy with pulmonary resection
  16. Oral ß-adrenergics.
  17. Oral corticosteroid medication at unstable doses
  18. Regular use of daytime oxygen therapy for more than one hour per day
  19. Pulmonary rehabilitation program in the six weeks prior to the screening visit
  20. Investigational drug within one month or six half lives (whichever is greater) prior to screening visit
  21. Known hypersensitivity to ß-adrenergic drugs, BAC, EDTA
  22. Pregnant or nursing women.
  23. Women of childbearing potential not using a highly effective method of birth control
  24. Patients who are unable to comply with pulmonary medication restrictions
separator

Contacts and Locations


Physicians:
James Tita, DO
Vijay Mahajan, MD
Srinivas Katragadda, MD

Coordinators:
Lisa Graham, RN, CCRC
Kristen Miller, BSN, CCRC

Please contact us at 419-251-4919 for more information about this study.
www.mercyweb.org
follow us online
facebook youtube


Contact us
Home  |  Sitemap

Disclaimer & Terms of Use  |  Privacy Statement  |  Notice of Privacy Practices
Copyright ©2013 Mercy. Last modified 10/17/2011